Leuprolide acetate Depot suspension will be reported using the J9217 HCPCS code. The dose unit for the code is 7.5 mg. Accurate dose conversion, diagnosis coding, product identification and administration documentation are all important for correct billing. There could also be coverage and authorization requirements that are unique to payers.
What Is the J9217 HCPCS Code?
Leuprolide acetate for depot suspension, 7.5 mg, is commonly known as this code. It is a HCPCS code used for reporting eligible leuprolide depot products. The code does not represent one entire injection regardless of dosage. Instead, each unit represents 7.5 mg of leuprolide acetate.
| Code | Description | Billing unit |
|---|---|---|
| J9217 | Leuprolide acetate for depot suspension | 7.5 mg |
| J9218 | Leuprolide acetate injection | 1 mg |
| J9219 | Leuprolide acetate implant | Implant |
What Drug Does J9217 Represent?
The code for leuprolide acetate (depot suspension) as this code. Leuprolide belongs to a group of drugs called gonadotropin-releasing hormone agonists. These drugs are used in a number of medical treatment situations. The HCPCS code selected should be the specific product, formulation, dosage, and indication. Leuprolide is included in the LHRH analogs coverage guidance provided by CMS, and there are covered diagnosis groupings. For instance, the current LUPRON DEPOT label will feature 7.5 mg, 22.5 mg, 30 mg, and 45 mg depot doses of the drug for advanced prostate cancer.
How Many Milligrams Equal One J9217 Unit?
There are 7.5 mg of leuprolide acetate in one unit. Each dose will contain a number of units depending upon the total dose administered.
The following calculation will be used:
J9217 units = Total dose administered ÷ 7.5 mg
| Dose administered | units |
|---|---|
| 7.5 mg | 1 unit |
| 15 mg | 2 units |
| 22.5 mg | 3 units |
| 30 mg | 4 units |
| 45 mg | 6 units |
These calculations align with CMS billing guidance for the different depot strengths.
How Are J9217 Billing Units Calculated?
The total dose administered is used for billing with units. The number of HCPCS units is not solely based on the vial, syringe or package count. For instance, 3 J9217 units are equivalent to 22.5mg of documentation. Six doses of this code is equal to a 45mg dose. This calculation should always be the same as the product and dosage recorded in the medical record. Claim errors, payment errors, and compliance issues can all occur due to incorrect unit conversion.
What Are Common J9217 Dosages?
J9217 dosing depends on the specific depot formulation and treatment schedule. Current LUPRON DEPOT labeling lists four prostate cancer dosing strengths.
| Depot strength | Administration schedule | units |
|---|---|---|
| 7.5 mg | Every 4 weeks | 1 |
| 22.5 mg | Every 12 weeks | 3 |
| 30 mg | Every 16 weeks | 4 |
| 45 mg | Every 24 weeks | 6 |
The current product label states that these formulations have different release characteristics. Therefore, the strengths should not be combined or treated as interchangeable.
What Conditions Support J9217 Billing?
J9217 coverage depends on the documented diagnosis, product indication, payer policy, and treatment circumstances. Medicare coverage guidance specifically identifies diagnosis groups associated with LHRH analog therapy.
Advanced prostate cancer is an important indication for several leuprolide depot products. CMS’s current billing article also includes additional diagnosis categories for this code under its applicable coverage groups. Coders should never select a diagnosis simply because it commonly accompanies leuprolide treatment. The medical record must support the condition being treated.
J9217 Billing and Coding Guidelines
Accurate billing requires the drug quantity to match the documented administered dose. The claim should also identify the appropriate diagnosis and associated administration service.
Important billing considerations include:
- Confirm the product is leuprolide acetate for depot suspension.
- Verify the dosage administered.
- Convert the dosage into 7.5 mg billing units.
- Select the diagnosis supported by documentation.
- Verify payer coverage requirements.
- Check prior authorization requirements.
- The report required NDC information.
- Document the administration service.
- Confirm the product’s NDC and dosage.
- Review payer-specific billing instructions.
CMS’s LHRH analog article was revised for dates of service beginning April 1, 2026.
Does J9217 Include Injection Administration?
No. this code reports the leuprolide drug, while the administration service is reported separately when applicable. CMS coding guidance has identified CPT 96402 for administration of certain GnRH analog injections, including this code. The actual administration code should always be confirmed against current CPT and payer requirements. The medical record should document the administration method and treatment details. This supports both the drug claim and the associated administration service.
What Modifiers Apply to J9217?
This code does not require one universal modifier for every claim. Modifier selection depends on the service circumstances, payer instructions, and associated procedure. Common modifiers should only be used when their specific coding requirements are met.
| Modifier | Potential application |
|---|---|
| JW | Eligible discarded drug from a qualifying single-dose container |
| JZ | No discarded drug from an applicable single-dose container |
| 59 | Distinct procedural service when separately reportable and documented |
| RT/LT | Laterality when required by the associated service or payer |
Do not add modifiers simply because they appear on a payer’s general modifier list. Documentation must support every modifier reported.
Does J9217 Require NDC Reporting?
NDC reporting requirements depend on the payer and claim format. When an NDC is required, it should identify the actual leuprolide product administered. The NDC should match the product documented in the medication record. Package information can help verify the correct NDC before claim submission.
Important drug identification details can include:
- HCPCS code
- Product name
- NDC
- Dosage strength
- Manufacturer
- Lot number
- Expiration date
- Date administered
- Dose administered
Some Medicaid and commercial payer policies specifically require NDC reporting for drug claims. Therefore, billing teams should verify the applicable payer instructions.
What Documentation Supports J9217 Billing?
Documentation should establish the patient’s condition, medication administered, dosage, and treatment schedule. It should also support medical necessity and the reported administration service.
A complete record may include:
- Patient diagnosis
- Clinical indication
- Medication name
- Product strength
- Dose administered
- Administration date
- Injection route
- Injection site
- NDC when required
- Lot number
- Expiration date
- Administration details
- Medical necessity
- Prior authorization information when applicable
The documented dose is particularly important because this code units are directly tied to 7.5 mg increments.
J9217 Medical Necessity and Coverage
Coverage for this code depends on the indication and applicable payer policy. Medicare’s current LHRH analog billing article provides diagnosis groups supporting coverage for certain uses. CMS identifies this code within its LHRH analog coverage guidance. The article also specifies that coverage policies should be considered alongside applicable LCD requirements. Commercial insurers may use different medical necessity criteria. Prior authorization may also be required before administering certain depot formulations.
J9217 Medicare Reimbursement
J9217 is priced under the Medicare Part B drug payment system. The applicable payment limit can change between quarterly files. CMS’s 2026 Part B drug payment page currently provides January, April, July, and October payment files. The October 2026 file is identified as preliminary, while July 2026 is listed as final and revised.
For Q3 2026, this code has a published Medicare payment limit of $160.342 per 7.5 mg unit in the CMS-derived payment data. This amount should not be treated as a guaranteed claim payment. Actual reimbursement can depend on payment methodology, claim circumstances, payer adjustments, and the applicable date of service.
Does J9217 Have an RVU?
J9217 is a drug HCPCS code, not a physician service reported through standard work RVUs. CMS identifies this code with a drug pricing indicator and a medical care type of service. Drug payment limits are therefore more relevant when reviewing reimbursement for the HCPCS code. The associated administration service can have separate CPT valuation and RVU information. Those values should not be confused with the drug’s payment amount.
J9217 Billing Example
Suppose a provider administers a 22.5 mg leuprolide depot injection. The documented dose supports three units.
The claim calculation would be:
22.5 mg ÷ 7.5 mg = 3 units
| Claim element | Example |
|---|---|
| HCPCS | J9217 |
| Dose | 22.5 mg |
| Units | 3 |
| Drug | Leuprolide acetate depot suspension |
| Diagnosis | Supported condition |
| Administration | Applicable administration code |
| NDC | Actual product NDC, when required |
The claim should reflect the actual product and dosage documented in the medical record. Supporting administration documentation should also be available.
Common J9217 Billing Errors
J9217 claims can be denied when billing units do not match the documented dose. Errors may also occur when the wrong leuprolide formulation or HCPCS code is selected.
Common errors include:
- Reporting one unit for every injection
- Using vial count instead of dosage units
- Reporting incorrect 7.5 mg conversions
- Selecting an unsupported diagnosis
- Omitting required NDC information
- Using an incorrect NDC
- Missing authorization requirements
- Failing to document administration
- Reporting unsupported modifiers
- Using outdated payer guidance
A claim review should compare the HCPCS quantity against the actual dosage administered.
How to Audit J9217 Claims
An audit should confirm that the product, dosage, diagnosis, and claim quantity are consistent. The review should also verify applicable coverage and administration requirements.
Use these questions during an audit:
- Was the correct leuprolide depot formulation administered?
- Does the documented dose match billed units?
- Was the 7.5 mg billing unit used correctly?
- Does the diagnosis support medical necessity?
- Was the appropriate administration service reported?
- Is the NDC accurate when required?
- Was prior authorization obtained when applicable?
- Are reported modifiers supported?
- Does the payer policy allow the treatment?
- Does the claim match the medical record?
These checks can identify common unit, product, documentation, and coverage problems.
Key Takeaways for J9217 Billing
J9217 HCPCS code refers to leuprolide acetate, depot suspension (7.5 mg/billing unit). Correct unit calculation is a key component of the process of submitting a drug claim. The 22.5 mg dose is usually three times the amount of J9217 units. Four units are 30 mg, 6 units are 45 mg. The proper diagnosis coding, product identification, documentation, administration reporting, and coverage review by the payers are also important for correct billing. Each quarterly CMS file should be used to check Medicare payment limits.
